NO20072206L - Fremgangsmate for a undersoke Alzheimers sykdom og diagnostisk reagens - Google Patents
Fremgangsmate for a undersoke Alzheimers sykdom og diagnostisk reagensInfo
- Publication number
- NO20072206L NO20072206L NO20072206A NO20072206A NO20072206L NO 20072206 L NO20072206 L NO 20072206L NO 20072206 A NO20072206 A NO 20072206A NO 20072206 A NO20072206 A NO 20072206A NO 20072206 L NO20072206 L NO 20072206L
- Authority
- NO
- Norway
- Prior art keywords
- disease
- alzheimer
- amyloid
- investigating
- procedures
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/539—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
- G01N33/541—Double or second antibody, i.e. precipitating antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004314639 | 2004-10-28 | ||
| JP2005052003 | 2005-02-25 | ||
| PCT/JP2005/019787 WO2006046644A1 (ja) | 2004-10-28 | 2005-10-27 | アルツハイマー病の検定方法及び診断試薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20072206L true NO20072206L (no) | 2007-07-30 |
Family
ID=36227886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20072206A NO20072206L (no) | 2004-10-28 | 2007-04-30 | Fremgangsmate for a undersoke Alzheimers sykdom og diagnostisk reagens |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20080199879A1 (de) |
| EP (1) | EP1813947A4 (de) |
| JP (1) | JPWO2006046644A1 (de) |
| KR (1) | KR20070073778A (de) |
| CN (1) | CN101048662A (de) |
| AU (1) | AU2005297854A1 (de) |
| BR (1) | BRPI0516674A (de) |
| CA (1) | CA2585148A1 (de) |
| IL (1) | IL182540A0 (de) |
| MX (1) | MX2007005053A (de) |
| NO (1) | NO20072206L (de) |
| RU (1) | RU2007119535A (de) |
| WO (1) | WO2006046644A1 (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| PT2289909E (pt) | 2005-11-30 | 2015-02-10 | Abbvie Inc | Método de rastreio, processo de purificação de globulómeros a-beta não difundíveis, anticorpos selectivos contra os referidos globulómeros a-beta não difundíveis e processo para o fabrico dos referidos anticorpos |
| RU2432362C2 (ru) | 2005-11-30 | 2011-10-27 | Эбботт Лэборетриз | Моноклональные антитела и их применения |
| EP2361638B1 (de) | 2005-12-12 | 2014-01-15 | AC Immune S.A. | A beta 1-42 spezifische monoklonale Antikörper mit therapeutischen Eigenschaften |
| ES2409058T3 (es) * | 2006-04-13 | 2013-06-24 | Eidia Co., Ltd. | Método para someter a prueba la enfermedad de Alzheimer midiendo la tasa de degradación de beta-amiloide en sangre y reactivo de diagnóstico |
| MX2009000476A (es) | 2006-07-14 | 2009-01-28 | Ac Immune Sa | Anticuerpo humanizado contra beta amiloide. |
| JP4683298B2 (ja) * | 2006-08-21 | 2011-05-18 | アイシン精機株式会社 | 被検物質の免疫測定方法、及び免疫結合親和性解析の制御方法 |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| JP5930573B2 (ja) | 2007-03-01 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤の新規使用 |
| WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| WO2009016734A1 (ja) * | 2007-07-31 | 2009-02-05 | University Of Tsukuba | 軽度認知機能障害の検定方法 |
| BRPI0818623A2 (pt) * | 2007-10-05 | 2017-05-23 | Ac Immune Sa | composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal |
| ES2445590T3 (es) | 2007-10-05 | 2014-03-04 | Genentech, Inc. | Uso de anticuerpo anti-amiloide beta en enfermedades oculares |
| US8445649B2 (en) * | 2007-10-29 | 2013-05-21 | Tao Health Life Pharma Co., Ltd. | Antibody and use thereof |
| EP2344881A4 (de) * | 2008-09-26 | 2012-03-07 | Univ Melbourne | Biomarker für morbus alzheimer |
| ES2548913T3 (es) | 2009-09-11 | 2015-10-21 | Probiodrug Ag | Derivados heterocíclicos como inhibidores de glutaminil ciclasa |
| AU2010329844B2 (en) | 2009-12-11 | 2015-07-16 | Araclon Biotech, S.L. | Methods and reagents for improved detection of amyloid beta peptides |
| WO2011092796A1 (ja) * | 2010-01-28 | 2011-08-04 | パナソニック株式会社 | アミロイドβ測定方法 |
| EP2542549B1 (de) | 2010-03-03 | 2016-05-11 | Probiodrug AG | Glutaminylcyclase-hemmer |
| EA022420B1 (ru) | 2010-03-10 | 2015-12-30 | Пробиодруг Аг | Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5) |
| ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
| US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
| CA2806909C (en) | 2010-07-30 | 2019-12-17 | Ac Immune S.A. | Safe and functional humanized antibodies |
| CA2808187A1 (en) | 2010-08-14 | 2012-02-23 | Abbvie Inc. | Amyloid-beta binding proteins |
| US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
| US20140302532A1 (en) | 2011-04-12 | 2014-10-09 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury |
| EP2511296A1 (de) | 2011-04-12 | 2012-10-17 | Araclón Biotech, S. L. | Antikörper, Kit und Verfahren zur Bestimmung von Amyloidpeptiden |
| WO2012142300A2 (en) * | 2011-04-12 | 2012-10-18 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury resulting from a hypoxic event |
| US9541561B2 (en) | 2012-06-14 | 2017-01-10 | Electronics And Telecommunications Research Institute | Method for diagnosing Alzheimer's disease using biomaterial |
| JP5991666B2 (ja) * | 2012-07-04 | 2016-09-14 | 公立大学法人大阪市立大学 | アルツハイマー病を検出する方法及びキット |
| JP2016103980A (ja) * | 2013-03-08 | 2016-06-09 | パナソニックヘルスケア株式会社 | ハイブリドーマ及びモノクローナル抗体 |
| US11360098B2 (en) * | 2015-09-28 | 2022-06-14 | Quest Diagnostics Investments Llc | Amyloid beta detection by mass spectrometry |
| JP6875623B2 (ja) * | 2016-02-15 | 2021-05-26 | ノーベルファーマ株式会社 | 遺伝性疾患に関わるタンパク質の測定方法及び測定キット |
| EP3242134A1 (de) * | 2016-05-04 | 2017-11-08 | Euroimmun Medizinische Labordiagnostika AG | Assay zur diagnose einer neurologischen krankheit |
| EP3461819B1 (de) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Hemmer der glutaminylcyclase |
| CN113311153B (zh) * | 2021-05-12 | 2023-05-26 | 华中科技大学 | 一种用于阿尔茨海默病诊疗一体化的多功能的纳米粒子 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0411974A1 (de) * | 1989-07-05 | 1991-02-06 | N.V. Innogenetics S.A. | Monoklonale Antikörper gegen neurofibrillisches Gewirrantigen |
| US6610493B1 (en) * | 1993-06-17 | 2003-08-26 | Brigham And Women's Hospital | Screening compounds for the ability to alter the production of amyloid-β peptide |
| US5786180A (en) * | 1995-02-14 | 1998-07-28 | Bayer Corporation | Monoclonal antibody 369.2B specific for β A4 peptide |
| EP1270592B1 (de) * | 2001-06-12 | 2004-09-29 | Wiltfang, Jens | Monoklonaler Antikörper, mbAb 1E8, welcher für die zwei ersten N-terminalen Aminosäuren von Amyloid-beta-Peptiden spezifisch ist und dessen Verwendung zum Nachweis von Amyloid-beta Peptiden und/oder sAPPa |
| EP1427439A4 (de) * | 2001-08-10 | 2004-11-17 | Merck & Co Inc | Gamma-drei-protease |
| EP2292247A3 (de) * | 2002-03-05 | 2011-10-05 | Ramot at Tel Aviv University Ltd. | Immunisierende zusammensetzung und verfahren zur auslösung einer immunantwort gegen die beta-secretase-cleavage-stelle von amyloid-vorläuferprotein |
-
2005
- 2005-10-27 MX MX2007005053A patent/MX2007005053A/es unknown
- 2005-10-27 RU RU2007119535/15A patent/RU2007119535A/ru unknown
- 2005-10-27 WO PCT/JP2005/019787 patent/WO2006046644A1/ja active Application Filing
- 2005-10-27 CA CA002585148A patent/CA2585148A1/en not_active Abandoned
- 2005-10-27 EP EP05799253A patent/EP1813947A4/de not_active Withdrawn
- 2005-10-27 AU AU2005297854A patent/AU2005297854A1/en not_active Abandoned
- 2005-10-27 CN CNA2005800368046A patent/CN101048662A/zh not_active Withdrawn
- 2005-10-27 US US11/665,816 patent/US20080199879A1/en not_active Abandoned
- 2005-10-27 BR BRPI0516674-8A patent/BRPI0516674A/pt not_active Application Discontinuation
- 2005-10-27 JP JP2006543248A patent/JPWO2006046644A1/ja not_active Withdrawn
- 2005-10-27 KR KR1020077008426A patent/KR20070073778A/ko not_active Application Discontinuation
-
2007
- 2007-04-12 IL IL182540A patent/IL182540A0/en unknown
- 2007-04-30 NO NO20072206A patent/NO20072206L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL182540A0 (en) | 2007-09-20 |
| EP1813947A4 (de) | 2008-06-11 |
| MX2007005053A (es) | 2007-06-19 |
| CA2585148A1 (en) | 2006-05-04 |
| US20080199879A1 (en) | 2008-08-21 |
| WO2006046644A1 (ja) | 2006-05-04 |
| CN101048662A (zh) | 2007-10-03 |
| JPWO2006046644A1 (ja) | 2008-05-22 |
| RU2007119535A (ru) | 2008-12-10 |
| AU2005297854A1 (en) | 2006-05-04 |
| KR20070073778A (ko) | 2007-07-10 |
| EP1813947A1 (de) | 2007-08-01 |
| BRPI0516674A (pt) | 2008-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20072206L (no) | Fremgangsmate for a undersoke Alzheimers sykdom og diagnostisk reagens | |
| Lleo et al. | Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases | |
| CN106574930B (zh) | 评价脑内的淀粉样蛋白β肽蓄积状态的替代性生物标记物和其分析方法 | |
| Vandersteen et al. | A comparative analysis of the aggregation behavior of amyloid-β peptide variants | |
| US9709573B2 (en) | Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration | |
| ATE535535T1 (de) | Methoden für die diagnose von demenz und anderen neurologischen erkrankungen | |
| Nutu et al. | Evaluation of the cerebrospinal fluid amyloid-β1-42/amyloid-β1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders | |
| Dedong et al. | Analysis of interleukin-17 and interleukin-23 for estimating disease activity and predicting the response to treatment in active lupus nephritis patients | |
| BRPI0619748A8 (pt) | anticorpo monoclonal, polinucleotídeo, região variável de cadeia leve, região variável de cadeia pesada, composição, mistura, métodos para produzir um anticorpo, para preparar uma composição farmacêutica ou uma mistura, de diagnóstico de uma doença ou condição associada a amilóide, para determinar o grau de carga de placa amiloidogênica em um tecido, para diagnosticar uma predisposição para uma doença ou condição, para monitorar doença residual mínima e para prever responsabilidade de um paciente, uso de um anticorpo monoclonal e/ou uma parte funcional do mesmo e/ou uma composição farmacêutica ou uma mistura, linhagem celular de hibridoma, e, kits de teste | |
| JP2010514805A5 (de) | ||
| DK3171174T3 (en) | Lactoferrin for use in the diagnosis or prognosis of Alzheimer's disease | |
| WO2009152607A8 (en) | Methods and kits for diagnosing neurodegenerative disease | |
| EP1977234A4 (de) | Moleküle zur behandlung von lungenerkrankungen mit einer immunreaktion mit verbindungsgewebe in der lunge | |
| WO2006107962A3 (en) | Methods and products for evaluating an immune response to a therapeutic protein | |
| TW201033616A (en) | Urine and serum biomarkers associated with diabetic nephropathy | |
| Stewart et al. | Cheek cell–derived α-synuclein and DJ-1 do not differentiate Parkinson's disease from control | |
| JP2010537200A (ja) | 改善されたアルツハイマー診断法 | |
| US20130273573A1 (en) | Amyloid beta aggregates in cerebro spinal fluid as biomarkers for alzheimer's disease | |
| DK1535076T3 (da) | Polypeptid-biomarkörer til diagnose af Alzheimers sygdom | |
| Papa | Exploring the role of biomarkers for the diagnosis and management of traumatic brain injury patients | |
| Tamara et al. | ATR-FTIR spectroscopy as a pre-screening technique for the PMI assessment and DNA preservation in human skeletal remains–A review | |
| Post et al. | Toward a reliable distinction between patients with mild cognitive impairment and Alzheimer-type dementia versus major depression | |
| CN111630382A (zh) | α-共核蛋白病的测定、方法和治疗 | |
| BR112022000322A2 (pt) | Um biomarcador para doença de alzheimer com o uso de amostras de sangue de indivíduos clinicamente diagnosticados com doença de alzheimer | |
| CN109073661A (zh) | 用于神经学疾病的诊断的测定法 |